Recent News

• 03.16.2026 - Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• 03.09.2026 - Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
• 02.23.2026 - Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
• 02.17.2026 - Kyntra Bio to Participate in Upcoming Investor Conferences
• 12.02.2025 - FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
• 11.10.2025 - FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 03.16.2026 - EX-99.1 EX-99.1
• 03.16.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.16.2026 - 8-K Current report
• 03.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.07.2026 - EX-99.1 EX-99.1
• 01.07.2026 - 8-K Current report